About this Research Topic
Metastasis is the major cause of mortality in cancer patients. Metastases can be present at the time of diagnosis or can occur years or decades after the removal of the primary tumor and treatment. This long latency in the manifestation of recurrent metastatic disease is explained clinically by the persistence of quiescent tumor cells that disseminated early in the course of the disease from the primary tumor to select distant organs. These residing disseminated tumor cells (DTCs) at distant organs lay dormant and asymptomatic until reawakened to form overt metastases. Importantly, the quiescent nature of these “hibernating” DTCs facilitates their resistance to conventional therapies that target actively dividing tumor cells. Therefore, unraveling the biology of dormancy and reactivation of the residing DTCs to life-threatening lesions is of utmost importance in order to develop new therapeutic strategies to prevent the recurrent metastatic disease from ever emerging or to better treat these recurrent cancers. The mechanisms underlying the biology of tumor dormancy and their reactivation to overt metastases are just beginning to emerge thanks to a growing appreciation of the potentially chronic nature of some cancers and the development of experimental model systems for their study. In this Research Topic, we will follow the journey of circulating tumor cells (CTCs) dispatching from the primary site until their successful lodging into a new and foreign site to become DTCs. We will explore the intrinsic mechanisms along with microenvironmental cues and niches that they encounter during their journey that may dictate their fate. We welcome the submission of Original Research, Review, Opinion and Perspective articles covering the following sub-topics:
1) The clinical aspect and impact of tumor dormancy on cancer patients.
2) Experimental model systems and imaging modalities for studying early dissemination of CTCs and tumor dormancy and clinical evidence for early dissemination.
3) DTCs phenotypic heterogeneity.
4) Pro-dormancy niches (bone marrow, lung, liver, brain, and the perivascular niche).
5) Cellular mechanisms launched by DTCs for their survival, adaptation and long-term dormancy at different organ sites (stemness, autophagy, metabolic regulations).
6) Pro-metastatic niches (including pre-metastatic niche, ECM remodeling, and more).
7) The role of the immune system in dictating the survival and outgrowth of DTCs.
DB is a consultant for VujaDe Scienes.
1) The clinical aspect and impact of tumor dormancy on cancer patients.
2) Experimental model systems and imaging modalities for studying early dissemination of CTCs and tumor dormancy and clinical evidence for early dissemination.
3) DTCs phenotypic heterogeneity.
4) Pro-dormancy niches (bone marrow, lung, liver, brain, and the perivascular niche).
5) Cellular mechanisms launched by DTCs for their survival, adaptation and long-term dormancy at different organ sites (stemness, autophagy, metabolic regulations).
6) Pro-metastatic niches (including pre-metastatic niche, ECM remodeling, and more).
7) The role of the immune system in dictating the survival and outgrowth of DTCs.
DB is a consultant for VujaDe Scienes.
Keywords: Tumor dormancy, Minimal residual disease, Circulating tumor cells, Cancer recurrence, Tumor Microenvironment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
